Sarepta Therapeutics, Inc. (SRPT)

Market Cap	10.15B
Revenue (ttm)	1.64B
Net Income (ttm)	121.85M
Shares Out	95.52M
EPS (ttm)	1.22
PE Ratio	87.13
Forward PE	12.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	635,914
Open	109.50
Previous Close	108.41
Day's Range	106.04 - 110.00
52-Week Range	101.15 - 173.25
Beta	0.75
Analysts	Buy
Price Target	174.64 (+64.32%)
Earnings Date	Feb 26, 2025

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 1,314
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Financial Performance

In 2023, Sarepta Therapeutics's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.

Analyst Forecast

According to 22 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $174.64, which is an increase of 64.32% from the latest price.

Price Target

$174.64

(64.32% upside)

Analyst Consensus: Buy